 |
53 Diseases |  |
490 Trials |
|
490 Trials |  |
8927 News |  |
| «12...93949596979899100101102103...123124» |
- | Votrient (pazopanib) / Novartis
Journal: Metabolic Response by 18F-FDG PET/CT in Metastatic Malignant Struma Ovarii Treated With Targeted Therapies. (Pubmed Central) - Nov 14, 2020
We report a metabolic response assessed by F-FDG PET/CT in a 71-year-old woman with radioiodine-refractory metastatic MSO treated by targeted therapies (first line with lenvatinib and second line with pazopanib). This case of exceptional response also highlights the usefulness of F-FDG PET/CT for therapeutic assessment of targeted drugs in such a rare clinical entity of malignant MSO.
- | Preclinical, Journal: Activated FGF2 signaling pathway in tumor vasculature is essential for acquired resistance to anti-VEGF therapy. (Pubmed Central) - Nov 14, 2020
Lenvatinib, a multiple tyrosine kinase inhibitor including VEGFR and FGFR inhibition, showed marked antitumor activity against VEGFR2-Fc-expressing resistant tumors accompanied with a decrease in the area of tumor vessels and suppression of phospho-FGFR2 in tumors. Our findings reveal the key role that intercellular FGF2 signaling between pericytes and endothelial cells plays in maintaining the tumor vasculature in anti-VEGF therapy-resistant tumors.
- ||||| Keytruda (pembrolizumab) / Merck (MSD)
Clinical, Checkpoint inhibition: In the multicenter, open-label, phase 2 trial, investigators set out to examine lenvatinib plus pembrolizumab in patients with RCC whose disease has progressed following immune checkpoint inhibition. @ChungHanLee3 @sloan_kettering @KidneyCancer #IKCS2020 https://t.co/Zxfn7mP6at (Twitter) - Nov 13, 2020
- lenvatinib / Generic mfg.
[VIRTUAL] Product Theater: LENVIMA® Monotherapy as First-Line Treatment Option for Patients with Unresectable Hepatocellular Carcinoma () - Nov 13, 2020 - Abstract #AASLD2020AASLD_2413;
Supported by: Eisai Inc. │ Objectives: Evaluate the efficacy and safety from the REFLECT trial that supports the use of LENVIMA as a first-line treatment option in patients with unresectable HCC (uHCC) Review patient case with uHCC to highlight potential treatment outcomes and adverse event management strategies associated with LENVIMA
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open, PD(L)-1 Biomarker, IO biomarker: NeoPele: A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma (clinicaltrials.gov) - Nov 13, 2020
P2, N=20, Recruiting, Sponsor: Melanoma Institute Australia
│ Objectives: Evaluate the efficacy and safety from the REFLECT trial that supports the use of LENVIMA as a first-line treatment option in patients with unresectable HCC (uHCC) Review patient case with uHCC to highlight potential treatment outcomes and adverse event management strategies associated with LENVIMA Not yet recruiting --> Recruiting
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
New trial: Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Nov 12, 2020
P, N=600, Recruiting, Sponsor: Sun Yat-sen University
- | Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, Avastin (bevacizumab) / Roche
New P2 trial, Metastases: HAIC Combined With Bevacizumab and Toripalimab for Advanced Hepatocellular Carcinama (clinicaltrials.gov) - Nov 12, 2020
P2, N=30, Not yet recruiting, Sponsor: Sun Yat-sen University
- |||| Keytruda (pembrolizumab) / Merck (MSD)
🟣🟣🟣🐅#LarvolView CLEAR study: #pembro + #lenvatinib = ⬆️ in PFS, OS, and ORR as 1L for mRCC See reactions from 20 top oncologists including @DrChoueiri @JFabianMH @TiansterZhang @mlazqui List with links: https://t.co/XChgBACSlB Article: https://t.co/hpYFHdVObN (Twitter) - Nov 12, 2020
- |||| everolimus / Generic mfg., lenvatinib / Generic mfg.
Clinical, Head-to-Head: Lenvatinib 14-mg showed similar safety to the standard 18-mg dose of the agent, when combined w/ everolimus in the second-line treatment of patients w/ advanced RCC, but noninferiority could not be confirmed. @montypal @cityofhope @KidneyCancer #IKCS2020 https://t.co/u0BAglD4jt (Twitter) - Nov 11, 2020
- ||| Inlyta (axitinib) / Pfizer
HEOR: Cost of drugs ( month supply ) Inlyta is 15 k Cabo is 18 k Lenvima is 18 K Have to take cost of care into consideration (Twitter) - Nov 11, 2020
- everolimus / Generic mfg., lenvatinib / Generic mfg.
[VIRTUAL] Real-world clinical effectiveness of lenvatinib+everolimus (Len/ Eve) in a heavily pre-treated advanced/metastatic renal cell carcinoma (a/mRCC) population in the US community oncology setting: a retrospective chart review study () - Nov 11, 2020 - Abstract #IKCS2020IKCS_97;
- everolimus / Generic mfg., lenvatinib / Generic mfg.
[VIRTUAL] Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) of Lenvatinib+Everolimus vs Everolimus Monotherapy in Advanced Renal Cell Carcinoma (aRCC) () - Nov 11, 2020 - Abstract #IKCS2020IKCS_95;
- everolimus / Generic mfg., lenvatinib / Generic mfg.
[VIRTUAL] Phase 2 trial of lenvatinib at 2 starting doses + everolimus in renal cell carcinoma (RCC) () - Nov 11, 2020 - Abstract #IKCS2020IKCS_92;
- Keytruda (pembrolizumab) / Merck (MSD)
[VIRTUAL] Phase 2 trial of lenvatinib + pembrolizumab for progressive disease after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell (mcc) renal cell carcinoma (RCC): results by independent imaging review (IIR) and subgroup analyses () - Nov 11, 2020 - Abstract #IKCS2020IKCS_91;
- Keytruda (pembrolizumab) / Merck (MSD)
[VIRTUAL] Correlative serum biomarker analyses: lenvatinib (LEN) plus pembrolizumab (PEMBRO) in a phase 1b/2 trial in advanced renal cell carcinoma (RCC) () - Nov 11, 2020 - Abstract #IKCS2020IKCS_75;
- everolimus / Generic mfg., lenvatinib / Generic mfg.
[VIRTUAL] A retrospective study of real-world treatment patterns and out- comes in advanced/metastatic renal cell carcinoma (a/mRCC) patients treated with lenvatinib+everolimus (Len/Eve) in a heavily pretreated population in the United States (US) community oncology setting () - Nov 11, 2020 - Abstract #IKCS2020IKCS_64;
- everolimus / Generic mfg., lenvatinib / Generic mfg.
[VIRTUAL] A phase 2 study of lenvatinib (LEN) plus everolimus (EVE) in patients with advanced non-clear cell renal cell carcinoma (nc- cRCC) () - Nov 11, 2020 - Abstract #IKCS2020IKCS_60;
- |||||| Keytruda (pembrolizumab) / Merck (MSD)
Clinical, Checkpoint inhibition: Lenvatinib + pembrolizumab demonstrated encouraging antitumor activity in patients with metastatic clear cell RCC who had progressed on prior PD-1 or PD-L1 immune checkpoint inhibitor therapy. @ChungHanLee3 @sloan_kettering @KidneyCancer #IKCS2020 https://t.co/Z6woV38SaV (Twitter) - Nov 10, 2020
- || Keytruda (pembrolizumab) / Merck (MSD)
IMO Lenv+Pembro will need HR for PFS and OS around 0.5 or less to counter perception/actual toxicity of lenvatinib compared to cabo or axi. Will be very interesting also to see if PFS benefit of lenva/everolimus arm outweighs any tox. This could be good 2nd line treatment post IO (Twitter) - Nov 10, 2020
- ||| Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS
Clinical: Where does Pembro + Lenvima stand in comparison to Pembro + Axitnib? Also with Nivo + Cabo data out there Lenvima is not the easiest drug to tolerate . Dosing can be complicated which can confuse patients (Twitter) - Nov 10, 2020
- ||| Keytruda (pembrolizumab) / Merck (MSD), Sutent (sunitinib) / Pfizer
Another front line TKI+I/O combo looking good as lenvatinib+pembrolizumab beats sunitinib in OS,PFS, and ORR in #RCC This trial is different than the others—> importantly, it also had a third arm (lenvatinib + everolimus) that beat sunitinib. #kcsm https://t.co/cxk2ldcjPC (Twitter) - Nov 10, 2020
- ||| lenvatinib / Generic mfg.
Lenvatinib + pembrolizmab with OS PFS and RR benefit in front line RCC . lenvatinib + everolumus with RR and PFS. This may have an impact on 1st and 2nd line therapy as lenvatinib + everolumus now has PFS in a R3. Looking forward to seeing the data . https://t.co/M4qFDXq8WN (Twitter) - Nov 10, 2020
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial: NEOplus: Lenvatinib and Pembrolizumab in Resectable Mucosal Melanoma (clinicaltrials.gov) - Nov 9, 2020
P2, N=26, Not yet recruiting, Sponsor: Beijing Cancer Hospital
- ||| everolimus / Generic mfg., lenvatinib / Generic mfg.
Upfront lenvatinib plus everolimus active in advanced non-clear cell renal carcinoma https://t.co/XDBorucAUL #kidneycancer #kidney #urology #urologist @DrTHut @TexasOncology (Twitter) - Nov 9, 2020
- || lenvatinib / Generic mfg.
Lenvatinib dose matters good work @montypal (Twitter) - Nov 8, 2020
- |||| lenvatinib / Generic mfg.
Clinical, Head-to-Head: Low-Dose Lenvatinib Shows Similar Safety to Standard Dose in RCC, But Noninferiority Cannot Be Claimed @montypal @cityofhope @KidneyCancer #IKCS2020 #kcsm https://t.co/UnXeBLuHDx (Twitter) - Nov 7, 2020
- ||||| everolimus / Generic mfg., lenvatinib / Generic mfg.
P2 data, Combination therapy: #IKCS2020 @montypal presents the results of large phase 2 trial Comparing two doses of lenvatinib (18 vs 14 mg) in combination with everolimus👉🏻Lenvatinib 18 mg remains the preferred dose in salvage Rx of metastatic #kidneycancer @EisaiUS @OncoAlert (Twitter) - Nov 7, 2020
- ||||| Keytruda (pembrolizumab) / Merck (MSD)
Lenvatinib/Pembrolizumab Shows Promise After PD-1/PD-L1 Inhibition in Metastatic Clear Cell RCC @ChungHanLee3 @sloan_kettering @KidneyCancer #IKCS2020 https://t.co/ixdEjK0KRa (Twitter) - Nov 7, 2020
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, Metastases: Phase II study on Lenvatinib in recurrent and/or metastatic adenoid cystic carcinomas (ACC) of the salivary glands of the upper aerodigestive tract Studio di fase II con Lenvatinib in pazienti affetti da carcinoma adenoide cistico delle ghiandole salivari, recidivato e/o metastatico (EUDRACT) - Nov 5, 2020
P2, N=26, Ongoing, Sponsor: FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI"
- ||| everolimus / Generic mfg., lenvatinib / Generic mfg.
Clinical: Valuable data on safety and efficacy of lenvatinib + everolimus by dose #IKCS2020 @montypal and team (Twitter) - Nov 5, 2020
- | Tyvyt (sintilimab) / Eli Lilly, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New trial: HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT (clinicaltrials.gov) - Nov 4, 2020
P=N/A, N=30, Not yet recruiting, Sponsor: Sun Yat-sen University
- ||||| everolimus / Generic mfg., lenvatinib / Generic mfg.
Clinical, P2 data: Phase 2 trial of lenvatinib at 2 starting doses + everolimus in renal cell carcinoma (RCC) Presented by: @montypal Very useful data for our clinical practice. #IKCS2020 @OncoAlert #GUcsm @cdanicas @docjavip @DrDanielHeng 🚩Currently approved dosing regimen is supported (Twitter) - Nov 4, 2020
- |||| lenvatinib / Generic mfg.
Is lenvatinib an immunotherapy or chemotherapy drug? https://t.co/GLPMIxfUAT #kidneycancer #Lenvima (Twitter) - Nov 4, 2020
- | Tevimbra (tislelizumab-jsgr) / BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, PD(L)-1 Biomarker: TALENT: Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC (clinicaltrials.gov) - Nov 3, 2020
P2, N=40, Not yet recruiting, Sponsor: Sun Yat-sen University
- | lenvatinib / Generic mfg.
Journal: Same-Day Repeat Hepatopulmonary Shunt Measurement during Planning Angiography for Hepatic Radioembolization. (Pubmed Central) - Nov 3, 2020
A patient with a 16.0 cm hepatocellular carcinoma and LSF of 70% was treated with lenvatinib for 4 weeks...The repeat LSF was 29%. Successful radioembolization was subsequently performed.
- || lenvatinib / Generic mfg.
Biomarker, Clinical, Journal: Conversion therapy for unresectable hepatocellular carcinoma after lenvatinib: Three case reports. (Pubmed Central) - Nov 3, 2020
This study demonstrated that LEN enables downstaging of HCC and thus represents a bridge to successful surgery or ablation therapy. In particular, LEN treatment may facilitate the possibility for conversion therapy of initially unresectable HCC, while maintaining the hepatic functional reserve.
- Nexavar (sorafenib) / Bayer, Amgen
[VIRTUAL] TRANSCRIPTIONAL LANDSCAPE OF HEPATOCELLULAR CARCINOMA REVEALS THAT PATIENT ANCESTRY INFLUENCES PATTERNS OF EXPRESSION () - Nov 2, 2020 - Abstract #AASLD2020AASLD_2113;
In particular, LEN treatment may facilitate the possibility for conversion therapy of initially unresectable HCC, while maintaining the hepatic functional reserve. In conclusion, we have outlined that the pathways involved in early hepatocarcinogenesis may occur in an ancestry-specific manner and that these distinct phenotypes should be taken into account during biomarker development.
- | Keytruda (pembrolizumab) / Merck (MSD)
Enrollment change: Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) (clinicaltrials.gov) - Nov 2, 2020
P1, N=1000, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
In conclusion, we have outlined that the pathways involved in early hepatocarcinogenesis may occur in an ancestry-specific manner and that these distinct phenotypes should be taken into account during biomarker development. N=400 --> 1000
- || lenvatinib / Generic mfg.
Cheaper than atezo bev. Lenvatinib about 7000 rs for 8 mg for one month. (Twitter) - Oct 31, 2020
- || Nexavar (sorafenib) / Bayer, Amgen
Lenvatinib cheaper than sorafenib? 😳 (Twitter) - Oct 31, 2020
- ||||| lenvatinib / Generic mfg.
Clinical: Case based discussion on HCC ... @ApolloProton @HospitalsApollo with the generic cheaper lenvatinib available now, this has become the first choice of treatment of our patients in india ! @Amolpatel_dr @VirajLavingia @GABOUALFA @ajumathew_ @ESOncology @oncology_bg @OncoAlert (Twitter) - Oct 31, 2020
- | lenvatinib / Generic mfg.
Journal: Lenvatinib for thyroid cancer treatment: discovery, pre-clinical development and clinical application. (Pubmed Central) - Oct 30, 2020
The decision to start a systemic treatment with lenvatinib must be personalized for each patient evaluating the risk/benefits ratio. Treatment emergent adverse events must be considered and reasonably managed by a multidisciplinary approach.
- || lenvatinib / Generic mfg.
Biomarker, Clinical, Clinical data, Journal: Hypothyroidism is a Predictive Factor for Better Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Undergoing Lenvatinib Therapy. (Pubmed Central) - Oct 30, 2020
An AE of Grade 2/3 hypothyroidism was associated with a better prognosis in patients receiving lenvatinib treatment for advanced HCC. Continuing anticancer therapy with appropriate thyroid hormone replacement may contribute to longer OS.
- Keytruda (pembrolizumab) / Merck (MSD), Avastin (bevacizumab) / Roche
[VIRTUAL] Leap-005: evaluating the safety and efficacy of lenvatinib and pembrolizumab in patients previously treated for ovarian cancer, a multi-cohort phase 2 study () - Oct 30, 2020 - Abstract #ESGO2020ESGO_292;
P1b/2, P2
Treatment-related adverse events occurred in 29 (94%) patients (table 1). View this table:View inline View popup Download powerpoint Abstract 297 Table 1 Conclusion Lenvatinib plus pembrolizumab demonstrated encouraging efficacy and manageable safety in patients with heavily pretreated ovarian cancer, including those with prior platinum failure and those with previous bevacizumab exposure
- | Keytruda (pembrolizumab) / Merck (MSD)
Enrollment change: KEYMAKER-U02 Substudy 02B: Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02) (clinicaltrials.gov) - Oct 29, 2020
P1/2, N=315, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
View this table:View inline View popup Download powerpoint Abstract 297 Table 1 Conclusion Lenvatinib plus pembrolizumab demonstrated encouraging efficacy and manageable safety in patients with heavily pretreated ovarian cancer, including those with prior platinum failure and those with previous bevacizumab exposure N=135 --> 315
- Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
[VIRTUAL] Presentation 3 () - Oct 29, 2020 - Abstract #ESGO2020ESGO_120;
N=135 --> 315 Brief overview of treatment approaches for MMRp EC patients Current Chemotherapy Future IO monotherapy (dostarlimab, pembrolizumab, avelumab) AI + CDKi (letrozole + palbociclib, NGOT-EN3/NSGO-PALEO study) VEGF + IO (lenvatinib + pembrolizumab, cabozantinib + nivolumab) Chemotherapy + IO (phase 3 trials in progress: pembrolizumab + chemotherapy, atezolizumab + chemotherapy, dostarlimab + chemotherapy [RUBY]) PARPi + IO + chemotherapy (FIRST trial) Considerations associated with chemotherapy vs IO monotherapy, VEGF/IO vs chemotherapy /IO combinations, including safety, PRO (if available)
- | Enrollment open: "Cocktail" Therapy for Hepatitis B Related Hepatocellular Carcinoma (clinicaltrials.gov) - Oct 28, 2020
P2, N=600, Recruiting, Sponsor: Yuehua Huang
Brief overview of treatment approaches for MMRp EC patients Current Chemotherapy Future IO monotherapy (dostarlimab, pembrolizumab, avelumab) AI + CDKi (letrozole + palbociclib, NGOT-EN3/NSGO-PALEO study) VEGF + IO (lenvatinib + pembrolizumab, cabozantinib + nivolumab) Chemotherapy + IO (phase 3 trials in progress: pembrolizumab + chemotherapy, atezolizumab + chemotherapy, dostarlimab + chemotherapy [RUBY]) PARPi + IO + chemotherapy (FIRST trial) Considerations associated with chemotherapy vs IO monotherapy, VEGF/IO vs chemotherapy /IO combinations, including safety, PRO (if available) Not yet recruiting --> Recruiting
- || lenvatinib / Generic mfg.
Clinical, Retrospective data, Journal: Early changes in ammonia levels and liver function in patients with advanced hepatocellular carcinoma treated by lenvatinib therapy. (Pubmed Central) - Oct 28, 2020
None of the patients discontinued lenvatinib therapy because of an adverse event. The ammonia levels of the study patients increased from baseline at 1 week after lenvatinib administration, but therapy could be continued for 4 weeks by appropriate management.
- | lenvatinib / Generic mfg.
Retrospective data, Journal: Lesion-based Evaluation Predicts Treatment Response to Lenvatinib For Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Korean Multicenter Retrospective Study. (Pubmed Central) - Oct 28, 2020
The ammonia levels of the study patients increased from baseline at 1 week after lenvatinib administration, but therapy could be continued for 4 weeks by appropriate management. Tumor doubling time calculations at the beginning of treatment and lesion-based tumor assessment may help identify potential responders to lenvatinib therapy and predict therapeutic responses.
- || Nexavar (sorafenib) / Bayer, Amgen
Clinical, Journal, Real-World Evidence: Extended Real-World Observation of Patients Treated with Sorafenib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Impact of Lenvatinib Salvage Treatment: A Korean Multicenter Study. (Pubmed Central) - Oct 28, 2020
The absence of disease-related symptoms and smaller tumor burden was associated with survival benefits of first-line sorafenib treatment in patients with progressive RAI-refractory DTC. Lenvatinib salvage therapy was effective in improving OS in patients with disease progression after first-line sorafenib.